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Abstract
The aim of this study was to identify the combinations of chronic comorbidities associated with length of stay (LOS) among
multimorbid medical inpatients.
Multinational retrospective cohort of 126,828 medical inpatients with multimorbidity, defined as ≥2 chronic diseases (data
collection: 2010–2011). We categorized the chronic diseases into comorbidities using the Clinical Classification Software. We
described the 20 combinations of comorbidities with the strongest association with prolonged LOS, defined as longer than or equal
to country-specific LOS, and reported the difference in median LOS for those combinations. We also assessed the association
between the number of diseases or body systems involved and prolonged LOS.
The strongest association with prolonged LOS (odds ratio [OR] 7.25, 95% confidence interval [CI] 6.64–7.91, P<0.001) and the
highest difference in median LOS (13 days, 95% CI 12.8–13.2, P<0.001) were found for the combination of diseases of white blood
cells and hematological malignancy. Other comorbidities found in the 20 top combinations had ORs between 2.37 and 3.65 (all with
P<0.001) and a difference in median LOS of 2 to 5 days (all with P<0.001), and included mostly neurological disorders and chronic
ulcer of skin. Prolonged LOS was associated with the number of chronic diseases and particularly with the number of body systems
involved (≥7 body systems: OR 21.50, 95% CI 19.94–23.18, P<0.001).
LOS was strongly associated with specific combinations of comorbidities and particularly with the number of body systems
involved. Describing patterns of multimorbidity associated with LOS may help hospitals anticipate resource utilization and judiciously
allocate services to shorten LOS.
Abbreviations: CCS=Clinical Classification Software, CI= confidence interval, ICD= International Classification of Diseases, IQR
= interquartile range, LOS = length of stay, OR = odds ratio.
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1. Introduction
The length of hospital stay (LOS) is a commonly used measure of
health care resource utilization.[1] Although it is directly
associated with health care costs in countries with a charging
system based on the number of hospital days, it has gained further
interest from health care providers in countries with a charging
system based on diagnosis-related groups.[2] Previous studies
showed that the LOS could be efficiently reduced through
different interventions, such as twice-daily consultant ward
round, interdisciplinary geriatric care, functional maintenance
program, or nurse-led interventions.[3,4] It is therefore important
to identify factors associated with a longer LOS so that such
services could potentially be targeted.
Multimorbidity, assessed simply as a number of conditions or
with the Charlson Comorbidity Index, has been associated with a
longer LOS.[5–8] Furthermore, some data suggest that multi-
morbidity is associated with long-term dependency, which in turn
can increase the risk of hospitalization and delay discharge, thus
extending the LOS.[9] However, which combinations of chronic
comorbidities are associated with a longer LOS has not been
well studied. Little is known as well about some potentially
more complex effects of multimorbidity on the LOS, such as
interactions between comorbidities that may have multiplicative
effects on the LOS.
The primary aim of our study was to identify combinations of
chronic comorbidities associated with LOS in multimorbid
medical inpatients, to quantify this association, and to assess
potential multiplicative effects of these comorbidities on the LOS.
The secondary aim was to quantify the association between the
LOS and the number of chronic diseases and body systems
involved.
2. Methods
2.1. Study design, setting and population
We used a retrospective cohort of medical inpatients aged ≥18
years, with multimorbidity (defined as ≥2 chronic diseases)[10,11]
and discharged home or to a nursing home from 11 large
hospitals across three countries (7 hospitals in the United States, 3
hospitals in Switzerland, and 1 hospital in Israel) during calendar
years 2010 to 2011 (detailed list of hospitals in Appendix, http://
links.lww.com/MD/E691). The cohort was initially built to study
readmission.[12] All data, including International Classification
of Diseases (ICD) diagnosis codes available at discharge, were
extracted from electronic medical records. The ethical committee
of each participating site approved the data collection. Because
this study falls under a further use of existing fully anonymized
data, the study was exempt from further Institutional Review
Board review. This study is in accordance with the STrengthening
the Reporting of OBservational studies in Epidemiology
(STROBE) statement.[13] The dataset is not publically available,
but can be requested from the corresponding author on
reasonable request (caroleelodie.aubert@insel.ch).
2.2. Classification of diseases
We included only chronic diseases according to the Chronic
Condition Indicator of the Healthcare Cost and Utilization
Project (HCUP), a Federal-State-Industry partnership sponsored
by the Agency for Healthcare Research and Quality.[14] This tool
defines a chronic disease as a condition lasting at least 12 months
and placing limitations on self-care, independent living and social
interactions and/or resulting in the need for ongoing intervention
with medical products, services, and special equipment. We
grouped all ICD codes classified as chronic diseases into a
clinically meaningful and more reasonable number of comor-
bidities using the Clinical Classification Software of the HCUP,
and into 18 body system categories using the Chronic Condition
Indicator (details in Appendix, http://links.lww.com/MD/
E691).[14,15] As previous authors, we excluded ICD codes for
screening strategies, symptoms, risk factors, and complica-
tions.[16,17] For clinical relevance, we further collapsed some
comorbidities together (details in Appendix, http://links.lww.
com/MD/E691).
2.3. Outcome
The outcome was the LOS, defined as the number of days
from hospital admission to hospital discharge. We used it as a
binary or as a continuous variable, depending on the analyses.
Because the LOS varied by country (e.g., longer in Switzerland
than in the United States), we defined a prolonged LOS as a LOS
longer than or equal to the country-specific upper (75%)
quartile.[18,19]
2.4. Statistical analyses
We present baseline characteristics as median with interquartile
range (IQR) or frequencies with percentage, as appropriate. For
the primary aim, we first used a mixed-effects logistic univariable
regression with a random intercept for center to identify the 20
combinations of comorbidities with the highest odds ratio (OR)
for a prolonged LOS, comparing patients with, to those without
the combination. Then, for these 20 combinations, we assessed
the difference in median LOS using quantile regression controlled
for center and calculated the attributable LOS, obtained by
multiplying the difference in median LOS by the number of
patients having the combination of comorbidities. Finally, we
analyzed the interactions among the comorbidities of each of
these 20 combinations on the odds of a prolonged LOS in mixed-
effects logistic regression and displayed the results as a
nonsignificant interaction, a more than multiplicative effect, or
a less than multiplicative effect. A more than multiplicative effect
means that the OR of the combination is higher than the ORs of
the single comorbidities multiplied together.
For the secondary aim, we used a mixed-effects logistic
univariable regression with a random intercept for center to
quantify the association between a prolonged LOS and the
number of chronic diseases, and the number of body systems
involved, and presented the results in forest plots.
We performed all analyses with STATA 15.1 (StataCorp LP,
College Station, TX) or R version 3.4.4 (R Project for Statistical
Computing).
3. Results
Among the 147,806 discharged patients available in the initial
cohort, 126,828 (86%) had multimorbidity and were included
for analysis (Fig. 1). Table 1 presents the baseline characteristics
of the patients in the whole population and according to
prolonged LOS. Median age was 64 years (IQR 52–76), median
number of chronic diseases was 5 (IQR 3–8), and median LOS
was 5 days (IQR 3–8). The most frequent comorbidities were
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chronic heart disease and chronic kidney disease, with a
prevalence of 48% and 18%, respectively.
3.1. Combinations of comorbidities and LOS
Diseases of white blood cells combined with hematological
malignancy showed the highest OR for a prolonged LOS (7.25,
95% confidence interval [CI] 6.64–7.91), the highest difference in
median LOS (13 days, 95% CI 12.8–13.2), and the highest
attributable LOS (29,744 days; Table 2). The 19 following
combinations increased the odds of a prolonged LOS by 137% to
265%, had a difference in median LOS of 2 to 5 days, and an
attributable LOS of 1280 days for chronic ulcer of skin with
peripheral and visceral atherosclerosis, to 10,248 days for
chronic ulcer of skin with chronic heart disease. These 19
combinations included mostly neurological diseases and chronic
ulcer of the skin. The comorbidities of 5 of the combinations had
a more than multiplicative effect on the odds of a prolonged LOS,
whereas those of 6 combinations had a less than multiplicative
effect.
3.2. Number of chronic diseases, number of body systems
involved, and LOS
Most patients had 3 or 4 chronic diseases (prevalence 14% for
each) and 3 body systems involved (prevalence 21%). TheOR for
a prolonged LOS exponentially increased with the number of
chronic diseases and particularly with the number of body
systems involved; the OR was 5.33 (95% CI 5.03–5.64) for
patients with ≥10 chronic diseases, and 21.50 (95% CI 519.94–
23.18) for those with ≥7 body systems involved (Fig. 2, details in
Appendix, http://links.lww.com/MD/E691).
Figure 1. Study flow-chart.
Table 1
Baseline characteristics.
Characteristics
Total population
(N=126,828)
LOS<upper quartile
(N=96,801)
LOS ≥ upper quartile
(N=30,027)
Age, y, median (IQR) 64 (52–76) 64 (52–76) 65 (52–77)
Men, n (%) 65,631 (51.7) 50,210 (51.9) 15,421 (51.4)
Country
United States, n (%) 82,937 (65.4) 64,731 (66.9) 18,206 (60.6)
Switzerland, n (%) 33,871 (26.7) 24,237 (25.0) 9634 (32.1)
Israel, n (%) 10,020 (7.9) 7833 (8.1) 2187 (7.3)
Description of multimorbidity
Deyo-Charlson Comorbidity Index, median (IQR)[1] 2 (1–3) 2 (1–3) 2 (1–4)
Elixhauser-Van Walraven Comorbidity Index, median (IQR)[2] 6 (1–12) 5 (0–12) 10 (4–16)
Number of chronic diseases, median (IQR) 5 (3–8) 5 (3–7) 6 (4–9)
Most prevalent comorbidities (prevalence ≥10%)
Chronic heart disease, n (%) 60,298 (47.5) 45,543 (75.5) 14,755 (24.5)
Chronic kidney disease, n (%) 22,210 (17.5) 15,733 (70.8) 6477 (29.2)
Mood disorders, n (%) 18,932 (14.9) 13,933 (73.6) 4999 (26.4)
Arthropathy and arthritis, n (%) 18,348 (14.5) 13,906 (75.8) 4442 (24.2)
Solid malignancy, n (%) 18,045 (14.2) 13,104 (75.6) 4941 (27.4)
Esophageal disorders, n (%) 17,864 (14.1) 13,896 (69.5) 3968 (22.2)
Other nervous system disorders, n (%) 16,349 (12.9) 11,354 (69.5) 4995 (30.6)
Chronic obstructive pulmonary disease and bronchiectasis, n (%) 14,696 (11.6) 10,652 (72.5) 4044 (27.5)
Thyroid disorders, n (%) 14,640 (11.5) 11,200 (76.5) 3440 (23.5)
Substance-related disorders, n (%) 12,863 (10.1) 9300 (72.3) 3562 (27.7)
Hospitalization characteristics
Length of stay, days, median (IQR) 5 (3–8) 4 (2–5) 14 (10–20)
Number of admissions in the past year, median (IQR) 0 (0–2) 0 (0–2) 1 (0–2)
IQR= interquartile range, LOS= length of stay, y= years.
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Table 2
Combinations of comorbidities and length of stay.
Combinations of comorbidities
OR
(95% CI) Interaction
Difference in median
LOS (95% CI)
∗
Attributable
LOS
Diseases of white blood cells Hematological malignancy 7.25 (6.64–7.91) + 13.0 (12.8–13.2) 29,744
Diseases of white blood cells Other nervous system disorders 3.65 (3.22–4.15) 0 4.0 (3.6–4.4) 3764
Paralysis Other nervous system disorders 3.28 (2.89–3.72) 0 4.0 (3.6–4.4) 3832
Paralysis Cerebrovascular disease 3.08 (2.80–3.40) + 5.0 (4.7–5.3) 8450
Cerebrovascular disease Other nervous system disorders 2.99 (2.68–3.34) + 3.0 (2.7–3.3) 3681
Paralysis Chronic heart disease 2.92 (2.64–3.23) 0 4.0 (3.7–4.3) 5864
Diseases of white blood cells Chronic heart disease 2.91 (2.67–3.17) 0 3.0 (2.8–3.3) 6108
Diseases of white blood cells Esophageal disorders 2.84 (2.52–3.20) 0 3.0 (2.6–3.4) 3033
Chronic ulcer of skin Chronic heart disease 2.74 (2.55–2.93) + 3.0 (2.9–3.2) 10,248
Chronic ulcer of skin Chronic kidney disease 2.62 (2.39–2.87) — 3.0 (2.8–3.3) 5664
Chronic ulcer of skin Arthropathy and arthritis 2.62 (2.38–2.88) + 3.0 (2.7–3.3) 4986
Hematological malignancy Chronic heart disease 2.57 (2.37–2.79) 0 2.0 (1.8–2.2) 4636
Diseases of white blood cells Mood disorders 2.54 (2.25–2.86) — 2.0 (1.6–2.4) 1948
Chronic ulcer of skin Paralysis 2.54 (2.20–2.92) — 3.0 (2.6–3.4) 2118
Chronic ulcer of skin Solid malignancy 2.51 (2.17–2.90) 0 3.0 (2.6–3.4) 1986
Diseases of white blood cells Chronic kidney disease 2.47 (2.15–2.85) — 2.0 (1.6–2.4) 1424
Chronic ulcer of skin Other nervous system disorders 2.46 (2.22–2.71) — 3.0 (2.7–3.3) 4866
Chronic ulcer of skin Chronic obstructive pulmonary
disease and bronchiectasis
2.43 (2.15–2.74) — 2.0 (1.6–2.4) 1906
Chronic ulcer of skin Peripheral and visceral atherosclerosis 2.41 (2.07–2.79) 0 2.0 (1.6–2.4) 1280
Chronic kidney disease Cerebrovascular disease 2.37 (2.07–2.72) 0 3.0 (2.6–3.4) 2592
CI= confidence interval, LOS= length of stay, OR= odds ratio.
∗
P<0.001 for all. A confidence interval not overlapping the zero line means that the difference in median LOS is significant.
Figure 2. Association between prolonged length of stay and (A) number of chronic diseases and (B) number of body systems involved. #, number of chronic
diseases (A)/body systems (B). Odds ratio (box) with 95% confidence interval (lines) for prolonged length of stay, defined as a length of stay longer than or equal to
country-specific upper (75%) quartile.
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4. Discussion
In this large multinational cohort of medical multimorbid
inpatients, we identified combinations of chronic comorbidities
associated with a prolonged LOS, quantified this association, and
assessed multiplicative effects of the comorbidities on the LOS.
Diseases of white blood cells with hematological malignancy
increased the odds of a prolonged LOS by 625% and had the
largest difference in median LOS (13 days). Other combinations
of comorbidities associated with prolonged LOS included mostly
neurological diseases and chronic ulcer of skin, and increased the
odds by 137% to 265%. One-fourth of the combinations of
comorbidities increased the odds of a prolonged LOS more than
expected, as revealed by the interaction analysis. The association
between LOS and the number of body systems was particularly
strong, reaching anOR of>20 for patients with ≥7 body systems
involved. This study identified chronic comorbidities with the
highest impact on LOS and pointed out the importance of
the number of chronic diseases and of body systems involved on
the LOS.
4.1. Combined comorbidities and LOS
With an odds of a prolonged LOS increased by 625% and a
difference in median LOS of 13 days for the combination of
diseases of white blood cells with hematological malignancy, the
association was far stronger than for other combinations; the
second top combination showed an association less than half as
strong, with an OR of 3.65 and a difference in median LOS of 4
days only. This strong association and particularly large
difference in median LOS could be mostly explained by the
neutropenia related to the hematological malignancy itself and/or
occurring as an expected consequence of the aplasia period
resulting from chemotherapy.[20] Previous authors indeed found
a median LOS of 16 days in patients with a hematological
malignancy and febrile neutropenia.[21] The LOS may unfortu-
nately be difficult to shorten, first because these patients most
often must stay in an isolated hospital room until bone-marrow
recovery occurs, and second because of the almost unavoidable
complications of aplasia, such as severe mucositis, that may
prevent enteral nutrition, and infections that most often occur
despite prophylactic drugs and strong hygiene practices.
Although one may argue that hematological malignancy and
diseases of white blood cells are part of a single pathology, they
are classified in different CCS and were therefore considered as
different comorbidities.
Neurological diseases combined together or with other
comorbidities were frequently identified in the next combinations
with the strongest association with a prolonged LOS. There may
be different explanations for this finding, partly depending on the
specific neurological diseases. First, for cerebrovascular diseases,
it may depend on the kind of care during hospitalization, as
inhospital interventions such as stroke units or care by neuro-
hospitalists could shorten the LOS in patients with stroke.[22,23]
Second, neurological diseases often result in disability, increasing
patients’ dependency and consecutive need for additional
supportive home care or discharge to a nursing home with
specialized care for paralysis or tracheotomy for example. This
might require some time to arrange due to limited resources,
which is a possibly modifiable factor. Third, we excluded patients
discharged to a rehabilitation facility and may thus hypothesize
that those patients with a neurological disease and prolonged
LOS included in our study may have been more severely affected
or too ill to qualify for rehabilitation care.
Diseases of white blood cells and chronic ulcer of the skin were
also very often found in the top combinations. Both comorbid-
ities are associated with an increased risk of infection and may
thus lead to complications prolonging LOS. Furthermore,
chronic ulcer of skin may require daily care that is not always
easy to organize outside of the hospital. Altogether, both
comorbidities may be seen as markers of frailty and of
multimorbidity severity.
The top 3 combinations with comorbidities increasing the odds
of a prolonged LOS more than expected (more than multiplica-
tive effect) included 2 combinations of neurological diseases, as
well as the combination of diseases of white blood cells with
hematological malignancy. Although we may have only little
influence on the LOS related to the latest, as discussed above,
particular attention should be focused on patients with
combinations of neurological diseases, as efficient interventions
may shorten the LOS in these patients.[3,22,23] The other 2
combinations with comorbidities with a more than multiplicative
effect both included chronic ulcer of the skin, underlying the
importance of adequate care to prevent this potentially avoidable
complication. It is worth noting that almost one-third of the
comorbidities found in the 20 top combinations had a less than
multiplicative effect on the odds for a long LOS, despite the
exponential relationship that we found with the number of
diseases. This suggests that the number of diseases may thus itself
not be sufficient to assess the real burden of multimorbidity.
4.2. Number of chronic diseases, number of body systems
involved, and LOS
Previous authors have described a longer LOS associated with the
number of diseases, with the Deyo-Charlson Comorbidity Index
or with multimorbidity assessed as present or absent, but none
had quantified this relationship with the number of chronic
diseases or body systems involved.[5,6,8,24] However, one study
found no significant difference in LOS between patients with
versus those without multimorbidity, but this study was small
(N=413), considered only 18 diseases in the assessment of
multimorbidity and included only surgical patients aged 65 years
or older, limiting the generalizability and comparability of the
results with our analyses.[25] We found a particularly strong
association between the LOS and the number of body systems
involved, with an OR reaching >20 for patients with ≥7 body
systems involved, suggesting that the number of body systems
involved, in addition to or instead of the number of diseases, may
simplify the assessment of the association between multi-
morbidity and adverse health outcomes.
4.3. Implications and explanations
The identification of combinations of comorbidities associated
with a prolonged LOS is important to identify patients most likely
to have a prolonged LOS. This may help hospitals to focus on
specifically high-risk patients to decrease the burden of multi-
morbidity and hospitalizations. Furthermore, the assessment of
combinations of comorbidities, and not only ofmultimorbidity as
a simple number of diseases, may help to focus on multimorbid
patients with potentially modifiable LOS, since not everything
can be influenced, as discussed for example for complications of
Aubert et al. Medicine (2020) 99:34 www.md-journal.com
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aplasia in patients with hematological diseases, and to develop
focused interventions according to specific diseases that are most
likely responsible for prolonging the LOS. Finally, the quantifi-
cation of the associations performed in this study may further
help to set priorities when aiming to shorten the LOS. Altogether,
this descriptive and quantitative detailed assessment of multi-
morbidity may help to identify patients on which we should
primarily focus preventive interventions to shorten the LOS, with
the final goal to reduce the burden of multimorbidity and health
care costs without decreasing quality of care.
4.4. Strengths and limitations
Our study presents some limitations. First, although we could
assess a broad number of diseases using ICD-codes, diagnoses are
subject to coding quality, so that we cannot exclude some
underreporting.[26,27] Second, our study was not designed to
assess causal relationships, so that remaining confounders are
possible and we can only describe associations. Finally, we
studied medical patients only, so that we cannot generalize our
findings to surgical patients, whose LOS may be further affected
by other reasons such as surgical complications.
This study has a number of strengths also. First, we used a large
multinational cohort, increasing results’ generalizability. Second,
we used standardized tools to define and classify the dis-
eases.[14,15] Third, unlike most previous studies limiting the
number of diseases to a specific and often subjective selection, we
considered all ICD-coded diagnoses. Finally, we assessed
multimorbidity using different innovative measures such as
combinations of comorbidities, number of chronic diseases and
number of body systems involved, and further studied multipli-
cative effects.
4.5. Conclusions, recommendations and future directions
In this large multinational study of multimorbid medical
inpatients, we identified combinations of comorbidities associat-
ed with a prolonged LOS, quantified these associations, and
assessed multiplicative effects of the different comorbidities on
the LOS. We found the strongest association for diseases of white
blood cells with hematological malignancy, whereas combina-
tions including neurological diseases and chronic ulcer of skin
increased the odds of a prolonged LOS by 137% to 265%. We
also quantified the association of the LOS with the number of
chronic diseases and the number of body systems involved and
found a particularly strong association with the latter. Further
studies would be warranted to assess a potential causal
relationship between combinations of diseases and the LOS.
Researchers could then first focus on patients with combinations
of diseases associated with a prolonged LOS and that may be
influenced to develop and test preventive interventions to shorten
the LOS and thus reduce the burden of multimorbidity and
hospitalizations.
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